MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MacroGenics, Inc.

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

MacroGenics

MacroGenics, Inc. | 14,863 followers on LinkedIn. MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies.  Our team of 300+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer. Our products and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe.

Vice President of Business Development at MacroGenics, Inc.

Harish Krishnaswamy

IT Director - Manufacturing, Quality and Supply Chain

Sharat Basapur

Director, QC Analysis at MacroGenics, Inc.

Carlos D. Vega

Hugh Graham

Why choose MacroGenics for your next CDMO project? ✅ Expertise in DS manufacturing ✅ Quality compliance at the forefront ✅ Prioritization of collaboration and communication Contact us at collaborate@macrogenics.com . #CDMO #Maryland

MacroGenics is a lifecycle collaborator. We are invested in your success and are here every step of the way. Our integrated offerings span cell line, process, and formulation development alongside clinical and commercial manufacturing, and release and stability testing. At MacroGenics, we treat your product as our own. Connect with us today at collaborate@macrogenics.com . #CDMO #Maryland

Comfort Cases, Inc. is a local non-profit organization that provides backpacks filled with comfort and personal care items for youth entering the foster care system. Comfort Cases distributes backpacks to foster care facilities in all 50 states. On October 15th, MacroGenics, Inc. employees donated their time to help at the local Comfort Cases corporate facility. The volunteers helped to build backpacks to be distributed to foster care facilities around the country, prepared donated blankets for packing, and organized inventory. We also helped to ship multiple boxes of backpacks to families impacted by recent hurricanes in Tampa, Florida. A sincere THANK YOU to all employees who volunteered to make a difference for children and young adults in the foster care system! #CommunityService #ComfortCases #NonProfit #MacroGenicsCares #MacroGenicsInTheCommunity #HurricaneMilton #Tampa #Florida

#PosterDay #CompanyEvents #Biotechnology #MacroGenics

Walter Nieto

“Do it Right” is one of our living values at MacroGenics; how we win is as important as winning itself. We strive for honest and transparent communications, mutual respect, stewardship and adherence to the highest ethical and quality standards. Contact us today at collaborate@macrogenics.com to find out how we can become your preferred CDMO partner of choice. #CDMO #Maryland

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	56.75M -	47.26M 16.72%	100.85M 113.38%	86.58M 14.15%	155.52M 79.62%	60.12M 61.34%	62.02M 3.17%	97.76M 57.62%	75.64M 22.63%	151.94M 100.87%	58.75M 61.33%
cost of revenue									2.65M -	7.38M 178.54%	619K 91.62%
gross profit	56.75M -	47.26M 16.72%	100.85M 113.38%	86.58M 14.15%	155.52M 79.62%	60.12M 61.34%	62.02M 3.17%	97.76M 57.62%	72.99M 25.34%	144.56M 98.04%	58.13M 59.79%
selling and marketing expenses
general and administrative expenses	11.09M -	15.93M 43.65%	22.77M 42.94%	29.83M 31.04%	32.65M 9.46%	40.50M 24.03%	46.06M 13.74%	42.74M 7.21%
selling general and administrative expenses	11.09M -	15.93M 43.65%	22.77M 42.94%	29.83M 31.04%	32.65M 9.46%	40.50M 24.03%	46.06M 13.74%	42.74M 7.21%	63.01M 47.43%	58.95M 6.45%	52.19M 11.47%
research and development expenses	46.58M -	70.19M 50.67%	98.27M 40.02%	122.09M 24.24%	147.23M 20.59%	190.83M 29.61%	195.31M 2.35%	193.20M 1.08%	214.58M 11.06%	207.03M 3.52%	166.58M 19.54%
other expenses	-626.81K -	2K 100.32%	42K 2,000%	1.51M 3,504.76%	2.52M 66.25%	-247K 109.81%	-2.16M 776.11%	-7.12M 228.97%	-1.80M 74.66%	1.66M 192.02%	7.60M 358.01%
cost and expenses	56.39M -	85.58M 51.77%	121.04M 41.43%	146.62M 21.14%	177.66M 21.17%	231.33M 30.21%	239.21M 3.41%	228.82M 4.34%	278.44M 21.68%	273.36M 1.82%	226.99M 16.96%
operating expenses	56.39M -	85.58M 51.77%	121.04M 41.43%	146.62M 21.14%	177.66M 21.17%	231.33M 30.21%	239.21M 3.41%	228.82M 4.34%	275.79M 20.52%	265.98M 3.56%	226.37M 14.89%
interest expense										263K -	-1.43M 643.73%
ebitda	1.56M -	-38.31M 2,557.16%	-17.32M 54.80%	-60.04M 246.68%	-22.14M 63.12%	-162.93M 635.79%	-166.34M 2.09%	-131.06M 21.21%	-202.79M 54.73%	-121.42M 40.13%	-168.24M 38.57%
operating income	365.98K -	-38.31M 10,569.18%	-20.18M 47.33%	-60.04M 197.50%	-22.14M 63.12%	-171.21M 673.18%	-177.19M 3.49%	-131.06M 26.03%	-202.79M 54.73%	-121.42M 40.13%	-168.24M 38.57%
depreciation and amortization	1.19M -	1.82M 52.68%	2.86M 57.14%	7.61M 165.74%	7.23M 4.99%	8.28M 14.54%	10.85M 30.99%	11.96M 10.25%	11.26M 5.85%	11.87M 5.39%
total other income expenses net	-626.81K -	2K 100.32%	42K 2,000%	1.51M 3,504.76%	2.52M 66.25%	-247K 109.81%	25.37M 10,372.87%	1.32M 94.79%	680K 48.52%	1.66M 144.12%	159.19M 9,489.52%
income before tax	-260.83K -	-38.31M 14,588.60%	-20.14M 47.43%	-58.53M 190.61%	-19.63M 66.47%	-171.45M 773.60%	-151.81M 11.46%	-129.74M 14.54%	-202.12M 55.79%	-119.76M 40.75%	-9.06M 92.44%
income tax expense		-1.82M -		-7.61M -	-7.23M 4.99%	-247K 96.58%		-11.96M -	-11.26M 5.85%	263K 102.34%
net income	-260.83K -	-38.31M 14,588.60%	-20.14M 47.43%	-58.53M 190.61%	-19.63M 66.47%	-171.45M 773.60%	-151.81M 11.46%	-117.78M 22.42%	-190.86M 62.04%	-120.02M 37.11%	-9.06M 92.45%
weighted average shs out	6.85M -	27.38M 299.92%	31.80M 16.13%	34.69M 9.07%	36.10M 4.06%	40.93M 13.38%	48.08M 17.49%	52.44M 9.07%	59.94M 14.31%	61.43M 2.48%	61.93B 100,707.50%
weighted average shs out dil	6.85M -	27.38M 299.92%	31.80M 16.13%	34.69M 9.07%	36.10M 4.06%	40.93M 13.38%	48.08M 17.49%	52.44M 9.07%	59.94M 14.31%	61.43M 2.48%	61.93B 100,707.50%
eps	-0.04 -	-1.40 3,574.54%	-0.63 55.00%	-1.69 168.25%	-0.54 68.05%	-4.19 675.93%	-3.16 24.58%	-2.25 28.80%	-3.18 41.33%	-1.95 38.68%	-0.00 99.99%
epsdiluted	-0.04 -	-1.40 3,574.54%	-0.63 55.00%	-1.69 168.25%	-0.54 68.05%	-4.19 675.93%	-3.16 24.58%	-2.25 28.80%	-3.18 41.33%	-1.95 38.68%	-0.00 99.99%

COM:MACROGENICS

MacroGenics

Last Close

3.21

22/11 21:00

Market Cap

267.45M

Beta: -

Volume Today

443.02K

Avg: -

Preview